

AMENDMENTS TO THE SPECIFICATION:

Please replace paragraphs [0001] and [0111] with the following amended paragraphs. The amendments to paragraph [0111] are shown in highlighting for the Examiner's convenience and double brackets are used in place of strikethrough because some of the deleted text includes hyphens.

[0001] This application is a division of and claims priority to U.S. Serial No. 09/951,265 filed on September 11, 2001, now U.S. Patent No. 6,605,617, which claims priority to U.S. Provisional Application No. 60/232,159 filed on September 11, 2000, the entire disclosure of which is incorporated herein by reference.

[0111] In preferred compounds of structure II, Y is selected from H, -OH, [[~~-OR⁹~~]] ~~-OR¹⁰~~ groups, or [[~~-NR¹¹R¹²]]~~ ~~-NR¹²R¹³~~ groups. More preferably, Y is a [[~~-NR¹¹R¹²]]~~ ~~-NR¹²R¹³~~ group. Still more preferably, Y is a [[~~-NR¹¹R¹²]]~~ ~~-NR¹²R¹³~~ group and both ~~R¹⁴~~ and ~~R¹²~~ R¹² and R¹³ are hydrogen. In other preferred compounds having the structure II, Y is selected from -N(CH₃)₂, -NH(CH₃), -NH(CH₂CH₃), -N(CH₂CH₃)₂, -NH(aryl) groups, -N(aryl)₂ groups, -NHNH₂, -NHN(CH₃)₂, -N(CH₃)NH(CH₃), -NH(CH₂)_mNH₂ groups, -NH(CH₂)_mNH(alkyl) groups, -NH(CH₂)_mN(alkyl)₂ groups, -N(alkyl)(CH₂)_mNH₂ groups, -N(alkyl)(CH₂)_mNH(alkyl) groups, -N(alkyl)(CH₂)_mN(alkyl)₂ groups, -NH(CH₂)_n(heterocyclyl) groups, -N(alkyl)[(CH₂)_n(heterocyclyl)] groups, -NH(CH₂)_mOH groups, -NH(CH₂)_mOCH₃ groups, -NHCH₂CH(NH₂)CH(CH₃)₂, -NH(2-aminocyclohexyl), -NH(cyclohexyl), -NHOCCH₃, -NH(N-morpholinyl), -NH(quinuclidyl), especially -NH(quinuclid-3-yl), and groups where ~~R¹⁴~~ and ~~R¹²~~ R¹² and R¹³ join to form a substituted or unsubstituted saturated 5 or 6 membered N-containing ring, where m is 2, 3, or 4 and n is 0, 1, 2, or 3. Still more preferred compounds of this type are those in which Y is selected from -NH(5-benzimidazolyl), -NH(CH₂)₂N(CH₃)₂, -NH(CH₂)₂OH, -NH(CH₂)(4-imidazolyl), -NH(CH₂)(3-imidazolyl), -NH(CH₂)(4-pyridyl), -NH(CH₂)(2-pyridyl), -NH(CH₂)(3-pyridyl), -NH(CH₂)(2-tetrahydrofuranyl), -NH(CH₂)(4-piperidinyl), -NH(CH₂)(3-piperidinyl), -NH(CH₂)₂[2-(N-methyl-pyrrolidinyl)], -NH(CH₂)₂(2-pyrrolidinyl), -NH(CH₂)₂[2-(N-methylpyrrolidinyl)], -NH(CH₂)(2-pyrrolidinyl), -NH(3-piperidinyl), or -NH(3-pyrrolidinyl).